In addition, the α-amylase and pancreatic lipase inhibition assays revealed significant enzyme inhibition, with the most potent derivative showing an α-amylase IC50 inhibition of 60.2 ± 0.8 μM and lipase IC50 inhibition of 100.6 ± 7.3 μM, suggesting its potential role in the management of metabolic disorders such as diabetes and obesity. Here, PNLIP is linked to metabolic disease.